Table 2.
Patient population classified by status of D353E (rs560191)
| Variable | CC–CG patients | GG patients | p Value |
|---|---|---|---|
| No. of patients | 124 | 52 | Not applicable |
| Age (mean) (y) | 38 | 44 | < 0.001 |
| Race | 30% AA | 69% AA | < 0.001 |
| 87% CA | 13% CA | ||
| T stage | 57% T1 | 52% T1 | 0.34 |
| 26% T2 | 34% T2 | ||
| 17% Tis | 13% Tis | ||
| N stage | 78% node negative | 71% node negative | 0.37 |
| ER status | 51% ER positive | 30% ER positive | 0.03 |
| PR status | 46% PR positive 36% | PR positive | 0.29 |
| HER2/Neu status | 34% HER2 positive | 31% HER2 positive | 0.81 |
| Margins | 4% positive | 6% positive | 0.91 |
| Family history | 17% strong | 25% strong | 0.28 |
| BRCA1/2 status | 11% positive | 8% positive | 0.57 |
| Adjuvant chemotherapy | 50% | 49% | 0.90 |
| Adjuvant hormones | 23% | 15% | 0.25 |
Abbreviations: ER= estrogen receptor; PR= progesterone receptor.